2025 Volume 15 Issue 6 Pages 44-48
In newly diagnosed multiple myeloma (NDMM), ixazomib (IXA) maintenance therapy for two years following autologous stem cell transplantation (ASCT) or induction therapy has demonstrated efficacy. However, the efficacy and safety of maintenance therapy beyond two years have not been well studied. We retrospectively analyzed 15 NDMM patients who received IXA maintenance therapy between March 2020 and March 2025. At initiation of maintenance therapy, 14 patients had achieved stringent complete response (sCR) and one had very good partial response (VGPR). Among patients with sCR, 12 achieved minimal residual disease (MRD)-negative status. The median duration of maintenance therapy was 809 days, with nine patients continuing beyond 2 years. Eight of these nine patients maintained sCR. Both hematologic and non-hematologic adverse events occurred but remained manageable with dose modifications and symptomatic treatment. Our findings suggest the feasibility and efficacy of long-term IXA maintenance therapy in multiple myeloma.
